A Comparative Effectiveness Study of Cancer Risk Management for Women at Elevated Genetic Risk of Ovarian Cancer
OBJECTIVES:
Primary
- To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year
saved, of risk-reducing salpingo-oophorectomy (RRSO) versus ovarian cancer screening
(OCS) for women at elevated genetic risk of ovarian cancer over a five-year period,
using data from GOG-0199 to model survival.
Secondary
- To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year
saved, of RRSO versus OCS for women at elevated genetic risk of ovarian cancer over a
lifetime, using stage-specific cohorts and population-based data to model long-term
survival. (Exploratory)
- To use value of information (VOI) methodology to set future research priorities aimed
at developing evidence-based approaches to the management of women who are at elevated
genetic risk of ovarian cancer. (Exploratory)
OUTLINE: Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube,
and peritoneal cancers; number and timing of screening and serum tests performed; number and
timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and
overall survival (if available); and the incidence, type, and grade of significant adverse
events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed.
Cost of each medical intervention is also estimated.
Interventional
Primary Purpose: Health Services Research
Cost-effectiveness of RRSO versus OCS
No
Laura J. Havrilesky, MD
Study Chair
Duke Cancer Institute
Unspecified
CDR0000712395
NCT01445275
October 2012
Name | Location |
---|